Stryker vows to reverse Europe woes; Medtronic CEO Ishrak goes full 'tweet' ahead;

 @FierceMedDev: Sony and Samsung are revving up their medtech rivalry. More | Follow @FierceMedDev

 @MarkHFierce: Dx investment continues, this time at Charles River Laboratories. Release | Follow @MarkHFierce

 @DamianFierce: The FDA wants feedback on its four-point plan to improve post-market surveillance for medical devices. Story | Follow @DamianFierce

> Stryker ($SYK) told investors that it has ceded market share in Europe and plans to refocus its efforts to better perform there. News

> As the medical device tax looms, KPMG surveyed execs in the industry, reporting that 55% are expecting to have trouble complying with the tax and 40% are considering cutting costs or raising prices to pay it. Article

> Innovative Trauma Care, a Canadian developer of wound care devices, is opening its U.S. headquarters in San Antonio. Item

> Accuray ($ARAY), a developer of radiation oncology medical devices, generated just over $100 million in net revenue during its fiscal 2012 fourth quarter, a decline over last year's combined revenue of Accuray and the now-acquired TomoTherapy. Release

> Medtronic ($MDT) CEO Omar Ishrak is among life sciences executives who have become avid tweeters. Story

> Medical devicemaker LDR Holding gained FDA clearance to market its Avenue L lateral lumber cage spinal device. Story

Biotech News

 @FierceBiotech: Respiratory virus tried as targeted cancer treatment. Story | Follow @FierceBiotech

 @JohnCFierce: Want to fix healthcare costs? IOM says there's $750B a year squandered in the U.S. Report | Follow @JohnCFierce

> Talent hunt spurs Sarepta's cross-country move to booming Boston hub. Story

> Safety threat forces AstraZeneca to scuttle obesity program. Report

> Promising PhIII apremilast data clear Celgene's path to the FDA. Article

> Pfizer partners on lung cancer drug in deal to speed Asian development. News

Pharma News

 @FiercePharma: GSK's Benlysta gets another shot at U.K. market. Story | Follow @FiercePharma

> Drug shortages ease but remain serious problem. Story

> J&J, Bayer try to answer FDA concerns on Xarelto. Report

> Loss of Makena suit against FDA compounds KV's problems. Article

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.